The gene-editing technology known as CRISPR has attracted much excitement and investor interest with its potential to someday treat diseases by fixing faulty copies of genes. But recently, a different approach called RNA editing, which could offer advantages over CRISPR, has been gaining ground in academic labs and start-ups, according to an article in Chemical & Engineering News (C&EN), the weekly newsmagazine of the American Chemical Society.
RNA editing uses an enzyme called ADAR to make precise edits to RNA, the shorter-lived cousin to DNA that acts as a blueprint for proteins. Researchers direct ADAR to specific RNAs with a guide sequence attached to the enzyme. Unlike CRISPR gene editing, the effects of RNA editing are reversible because cells are constantly making new copies of RNA. Therefore, RNA editing avoids the risks of permanent gene editing with CRISPR, writes Assistant Editor Ryan Cross, and could also be used to treat temporary conditions, such as pain or inflammation.
However, finding an easy way to control how ADAR makes its edits has been challenging. Researchers have tried chemically attaching ADAR to a guide RNA, adding an RNA-binding protein or even linking the catalytic portion of ADAR to the bacterial Cas9 enzyme used in CRISPR. However, these approaches require getting the modified enzymes into human cells. Some researchers are working on using human cells’ own ADAR for RNA editing, by introducing chemically modified guide RNAs that recruit the editing enzyme and direct it to specific RNAs. With researchers and investors becoming increasingly interested in this approach, RNA editing could someday give CRISPR a run for its money, Cross writes.
The article, “Watch out, CRISPR. The RNA editing race is on,” is freely available here.
Learn more: Interest in RNA editing heats up
The Latest on: RNA editing
via Google News
The Latest on: RNA editing
- Vico Therapeutics Appoints Micah Mackison as Chief Executive Officeron July 31, 2022 at 11:23 pm
Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the appointment of Micah Mackison as Chief Executive Officer. Mr. Mackison brings significant biotechnology and ...
- How ADAR1 mutation leads to self-destructive inflammationon July 28, 2022 at 9:37 am
A new study shows how mutation of the ADAR1 gene sets off biochemical pathways that produce an autoimmune response that harms the developing brain and other areas of the body.
- Treating inherited deafness with RNA base editingon July 24, 2022 at 11:30 pm
Using RNA base editing techniques, scientists have successfully reversed a genetic form of hearing loss in a mouse model.
- Researchers Uncover Protein Involved in Senescence and Tissue Agingon July 19, 2022 at 5:00 am
Researchers say that ADAR1, a protein involved in RNA editing, is now also revealed in senescence and its implications in tissue aging.
- Scientists reveal new function of enzyme ADAR1 linking it to age-related diseases via a role independent of RNA-editing during agingon July 18, 2022 at 12:08 pm
Scientists have revealed a novel ADAR1-SIRT1-p16INK4a axis in regulating cellular senescence and its potential implications in tissue aging.
- The function of enzyme ADAR1 links it to age-related diseases via a role independent of RNA-editing during agingon July 18, 2022 at 8:48 am
The research team's findings center around a protein called ADAR1. ADAR1 is a specialized enzyme involved in RNA editing and is now revealed in senescence. Postdoctoral researcher in the Zhang lab ...
- Wistar scientists reveal a novel ADAR1-SIRT1-p16INK4a axis in regulating cellular senescenceon July 17, 2022 at 4:59 pm
The research team's findings center around a protein called ADAR1. ADAR1 is a specialized enzyme involved in RNA editing and is now revealed in senescence. Postdoctoral researcher in the Zhang lab ...
- Non-CRISPR Gene Editing Platforms Make the Cut … or Avoid Making Iton July 9, 2022 at 7:34 am
Yet another resource for the genome editing field is the family of Adenosine Deaminase Acting on RNA (ADAR) enzymes. ADAR is used to edit RNA rather than DNA, but like CRISPR and ARCUS ...
- ProQR to Participate in the LifeSci 2nd Annual Genetic Medicines Symposiumon June 28, 2022 at 4:02 am
ProQR is pioneering a next-generation RNA technology called Axiomer®, which uses a cell’s own editing machinery called ADAR (adenosine deaminase acting on RNA) to make specific single ...
- Scientists Discover That a Squid Can Edit Its Own Genetic Codeon August 4, 2020 at 8:12 pm
Thus far, it's the only animal known to do so. "RNA editing is a hell of a lot safer than DNA editing," lead researcher Joshua Rosenthal told Wired. "If you make a mistake, the RNA just turns over ...
via Bing News